Heart & lung : the journal of critical care · 2025
Can apelins guide the diagnosis of coronary artery disease in COPD patients?
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aksakal Alperen, Kerget Buğra, Gülbahar Burcu Nur, Laloğlu Esra, Sağlam Leyla
Аннотация
BACKGROUND: Apelins are adipokines known for their anti-inflammatory, vasodilator, and antiatherosclerotic effects. They are involved in the pathogenesis of chronic diseases like chronic obstructive pulmonary disease (COPD) and coronary artery disease (CAD).
OBJECTIVES: This study aims to investigate apelin as a potential biomarker for early diagnosis and management of CAD in COPD patients.
METHODS: The study included 73 stable COPD patients admitted between June 2023 and June 2024 and 35 healthy volunteers matched by age and gender. COPD patients were categorized into two groups: those without CAD (Group 1) and those with CAD (Group 2). Serum levels of apelin 12, 13, 17, and 36 were measured using ELISA.
RESULTS: Serum apelin levels were significantly lower in COPD patients than in controls (p < 0.001). Among COPD patients, those with CAD showed lower serum apelin levels compared to those without CAD (p = 0.005 for apelin 12, p < 0.001 for apelin 13, 17, and 36). ROC analysis indicated high sensitivity and specificity for apelin 13 and 36 in predicting CAD in COPD patients. Apelin 13 and 36 were positively correlated with ejection fraction (EF) (R = 0.43, p = 0.01; R = 0.4, p = 0.01), and apelin 12 was positively correlated with FEV1 and FVC (R = 0.24, p = 0.04; R = 0.27, p = 0.02).
CONCLUSION: While CAD worsens the prognosis in COPD patients, it remains underdiagnosed. Serum apelin, especially apelin 13 and 36, may assist in the early diagnosis and management of CAD in COPD patients.
OBJECTIVES: This study aims to investigate apelin as a potential biomarker for early diagnosis and management of CAD in COPD patients.
METHODS: The study included 73 stable COPD patients admitted between June 2023 and June 2024 and 35 healthy volunteers matched by age and gender. COPD patients were categorized into two groups: those without CAD (Group 1) and those with CAD (Group 2). Serum levels of apelin 12, 13, 17, and 36 were measured using ELISA.
RESULTS: Serum apelin levels were significantly lower in COPD patients than in controls (p < 0.001). Among COPD patients, those with CAD showed lower serum apelin levels compared to those without CAD (p = 0.005 for apelin 12, p < 0.001 for apelin 13, 17, and 36). ROC analysis indicated high sensitivity and specificity for apelin 13 and 36 in predicting CAD in COPD patients. Apelin 13 and 36 were positively correlated with ejection fraction (EF) (R = 0.43, p = 0.01; R = 0.4, p = 0.01), and apelin 12 was positively correlated with FEV1 and FVC (R = 0.24, p = 0.04; R = 0.27, p = 0.02).
CONCLUSION: While CAD worsens the prognosis in COPD patients, it remains underdiagnosed. Serum apelin, especially apelin 13 and 36, may assist in the early diagnosis and management of CAD in COPD patients.